Physician profile
James Knight
NPI 1245402320
$1,544.64
in general payments reported to CMS, 2019-2025
21 companies · $33.21 in 2025
The $33.21 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $106 · 2021: $162 · 2022: $402 · 2023: $375 · 2024: $184 · 2025: $33.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $432 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $432.45 |
| Education | $160.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $258.77 | 2021-2023 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $211.13 | 2022-2024 | Dupixent |
| Insmed, INC. | $160.27 | 2019-2024 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $137.32 | 2022-2024 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $104.86 | 2019-2025 | Nucala |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Genentech USA, INC. | $76.57 | 2019-2023 | Xolair |
| Exthera Medical Corporation | $73.57 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $62.27 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.13 | 2019-2020 | |
| Philips North America LLC | $47.21 | 2022-2024 | (Ak6) Vest Therapy |
| Genzyme Corporation | $40.01 | 2023 | |
| Vifor Pharma, INC. | $39.46 | 2024 | Zemaira |
| Baxter Healthcare | $33.73 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Shire North American Group INC | $30.98 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $27.28 | 2022 | |
| Pinnacle Biologics, INC | $23.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.45 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.83 | 2020 | |
| Grifols USA, LLC | $16.22 | 2020 | |
| Boston Scientific Corporation | $12.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.